Sarcopenia and sarcopenic obesity are independent adverse prognostic factors in resectable pancreatic ductal adenocarcinoma

• DOI: 10.1371/journal.pone.0215915
• Publication Date: 2019-05-06T18:26:20Z
• Authors: Elisabeth S. Gruber; Gerd Jomrich; Dietmar Tamandl; Michael Gnant; Martin Schindl; Klaus Sahora
• Keywords: Sarcopenic obesity

Background Incidence and mortality of pancreatic ductal adenocarcinoma (PDAC) are on the rise. Sarcopenia sarcopenic obesity have proven to be prognostic factors in different types cancers. In context previous findings, we evaluated impact body composition patients undergoing surgery a national center. Methods Patient's (n = 133) was analyzed diagnostic CT scans defined as follows: Skeletal muscle index ≤38.5 cm2/m2 (women), ≤52.4 (men); classified BMI ≥25kg/m2. Results showed negative overall survival (OS; 14 vs. 20 months, p 0.016). Sarcopenic suffering from poorer OS compared non-sarcopenic obese (14 23 0.007). Both sarcopenia were associated with sex (p<0.001 0.006; males females 20% 38% 12% 38%, respectively); further neoadjuvant treatment (p 0.025), tumor grade 0.023), weight loss 0.02) nutritional depletion (albumin, 0.011) well low (<25 kg/m2, 0.038). higher incidence major postoperative complications (p<0.001). addition, proved an independent factor for 0.031) multivariable Cox Regression model. Conclusion Patients resection PDAC significantly shorter complication rate. The assessment these may provide broader understanding patients' individual condition guide specific supportive strategies at risk.